BCL2 and Alzheimer disease: cASC-EVs significantly reduced the level of inflammatory cytokines associated with AD (IL-4, IL-13, IL-31, RANTES). In addition, they promoted skin barrier repair by reducing TEWL, increasing stratum corneum hydration, and upregulating the expression of epidermal differentiation proteins ((AKT and BCL-2).